{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:30:55Z","timestamp":1792467055790,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1186\/s12879-017-2779-9","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T10:22:27Z","timestamp":1509531747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Economic evaluation of HCV testing approaches in low and middle income countries"],"prefix":"10.1186","volume":"17","author":[{"given":"Jake R.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Servidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2779_CR1","unstructured":"World Health Organization. Global Hepatitis Report, 2017. Geneva; 2017. http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ . Accessed 1 Sept 2017."},{"issue":"6","key":"2779_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/apt.13090","volume":"41","author":"Z Younossi","year":"2015","unstructured":"Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497\u2013520.","journal-title":"Aliment Pharmacol Ther"},{"key":"2779_CR3","unstructured":"World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016\u20132021: Towards Ending Viral Hepatitis. 2016. http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/ . Accessed 1 Sept 2017."},{"issue":"5","key":"2779_CR4","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Tay-Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.","journal-title":"PLoS Med"},{"key":"2779_CR5","unstructured":"World Health Organization. Guidelines on Hepatitis B and C Testing. Geneva; 2017. http:\/\/www.who.int\/hepatitis\/publications\/guidelines-hepatitis-c-b-testing\/en\/ . Accessed 29 Aug 2017."},{"issue":"7650","key":"2779_CR6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"2779_CR7","volume-title":"Cost effectiveness in health and medicine","author":"PJ Neumann","year":"2017","unstructured":"Neumann PJ, Russell LB, Sanders GD, Siegel JE, Ganiats TG. Cost effectiveness in health and medicine. 2nd ed. Oxford, New York: Oxford University Press; 2017.","edition":"2"},{"issue":"12","key":"2779_CR8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925\u201330.","journal-title":"Bull World Health Organ"},{"key":"2779_CR9","doi-asserted-by":"publisher","unstructured":"Nayagam S, Sicuri E, Lemoine M, Conteh L et al. Economic evaluations of HBV screening and treatment strategies and applicability to low and middle-income countries (LMICs). BMC Infect Dis. 2017;9. doi: 10.1186\/s12879-017-2778-x","DOI":"10.1186\/s12879-017-2778-x"},{"issue":"32","key":"2779_CR10","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta10320","volume":"10","author":"E Castelnuovo","year":"2006","unstructured":"Castelnuovo E, Thompson-Coon J, Pitt M, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10(32):iii\u2013v. ix\u2013xii, 1\u201393","journal-title":"Health Technol Assess"},{"issue":"3","key":"2779_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/liv.13240","volume":"37","author":"N Selvapatt","year":"2017","unstructured":"Selvapatt N, Ward T, Harrison L, et al. The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit. Liver Int. 2017;37(3):345\u201353.","journal-title":"Liver Int"},{"issue":"4","key":"2779_CR12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S026646230300059X","volume":"19","author":"S Loubiere","year":"2003","unstructured":"Loubiere S, Rotily M, Moatti JP. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care. 2003;19(4):632\u201345.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"2779_CR13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jms.6.3.124","volume":"6","author":"P Leal","year":"1999","unstructured":"Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen. 1999;6(3):124\u201331.","journal-title":"J Med Screen"},{"issue":"1","key":"2779_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/pubmed\/fdh109","volume":"26","author":"K Stein","year":"2004","unstructured":"Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in injecting drug users: a cost utility analysis. J Public Health (Oxf). 2004;26(1):61\u201371.","journal-title":"J Public Health (Oxf)"},{"issue":"4","key":"2779_CR15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/fampra\/cml032","volume":"23","author":"J Thompson Coon","year":"2006","unstructured":"Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract. 2006;23(4):393\u2013406.","journal-title":"Fam Pract"},{"issue":"1","key":"2779_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/add.12754","volume":"110","author":"BR Schackman","year":"2015","unstructured":"Schackman BR, Leff JA, Barter DM, et al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015;110(1):129\u201343.","journal-title":"Addiction"},{"issue":"9","key":"2779_CR17","doi-asserted-by":"crossref","first-page":"e45176","DOI":"10.1371\/journal.pone.0045176","volume":"7","author":"LE Cipriano","year":"2012","unstructured":"Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One. 2012;7(9):e45176.","journal-title":"PLoS One"},{"issue":"8","key":"2779_CR18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003153","volume":"3","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8):e003153.","journal-title":"BMJ Open"},{"issue":"11","key":"2779_CR19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2893.2008.01008.x","volume":"15","author":"AJ Sutton","year":"2008","unstructured":"Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008;15(11):797\u2013808.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2779_CR20","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/hep.28497","volume":"63","author":"NK Martin","year":"2016","unstructured":"Martin NK, Vickerman P, Brew IF, et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016;63(6):1796\u2013808.","journal-title":"Hepatology"},{"issue":"2","key":"2779_CR21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","volume":"164","author":"T He","year":"2016","unstructured":"He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84.","journal-title":"Ann Intern Med"},{"key":"2779_CR22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2458-6-170","volume":"6","author":"AJ Sutton","year":"2006","unstructured":"Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health. 2006;6:170.","journal-title":"BMC Public Health"},{"issue":"2","key":"2779_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/cis382","volume":"55","author":"BP Linas","year":"2012","unstructured":"Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012;55(2):279\u201390.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2779_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.215.33","volume":"215","author":"J Nakamura","year":"2008","unstructured":"Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the National Screening Program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008;215(1):33\u201342.","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"2779_CR25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/cis011","volume":"54","author":"PO Coffin","year":"2012","unstructured":"Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54(9):1259\u201371.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2779_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","volume":"58","author":"P McEwan","year":"2013","unstructured":"McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology. 2013;58(1):54\u201364.","journal-title":"Hepatology"},{"issue":"5","key":"2779_CR27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","volume":"55","author":"LJ McGarry","year":"2012","unstructured":"McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55(5):1344\u201355.","journal-title":"Hepatology"},{"issue":"4","key":"2779_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","volume":"156","author":"DB Rein","year":"2012","unstructured":"Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263\u201370.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2779_CR29","doi-asserted-by":"crossref","first-page":"e58975","DOI":"10.1371\/journal.pone.0058975","volume":"8","author":"S Liu","year":"2013","unstructured":"Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One. 2013;8(3):e58975.","journal-title":"PLoS One"},{"issue":"3","key":"2779_CR30","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1503\/cmaj.140711","volume":"187","author":"WW Wong","year":"2015","unstructured":"Wong WW, HA T, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015;187(3):E110\u201321.","journal-title":"CMAJ"},{"issue":"6","key":"2779_CR31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jval.2013.07.005","volume":"16","author":"M Ruggeri","year":"2013","unstructured":"Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic assessment of an anti-HCV screening program in Italy. Value Health. 2013;16(6):965\u201372.","journal-title":"Value Health"},{"issue":"10","key":"2779_CR32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/cid\/cit069","volume":"56","author":"MH Eckman","year":"2013","unstructured":"Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013;56(10):1382\u201393.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2779_CR33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/gut.2007.145516","volume":"58","author":"S Deuffic-Burban","year":"2009","unstructured":"Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Gut. 2009;58(1):105\u201310.","journal-title":"Gut"},{"issue":"9","key":"2779_CR34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jvh.12190","volume":"21","author":"AH Miners","year":"2014","unstructured":"Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014;21(9):616\u201323.","journal-title":"J Viral Hepat"},{"issue":"3","key":"2779_CR35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/17441692.2014.984742","volume":"10","author":"DD Kim","year":"2015","unstructured":"Kim DD, Hutton DW, Raouf AA, et al. Cost-effectiveness model for hepatitis C screening and treatment: implications for Egypt and other countries with high prevalence. Glob Public Health. 2015;10(3):296\u2013317.","journal-title":"Glob Public Health"},{"issue":"11","key":"2779_CR36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","volume":"107","author":"P Vickerman","year":"2012","unstructured":"Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984\u201395.","journal-title":"Addiction"},{"issue":"5","key":"2779_CR37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and nutrition examination survey 2003 to 2010. Ann Intern Med. 2014;160(5):293\u2013300.","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"2779_CR38","first-page":"54","volume":"97","author":"JT Lau","year":"2008","unstructured":"Lau JT, Tsui HY, Zhang Y, et al. Comparing HIV-related syringe-sharing behaviors among female IDU engaging versus not engaging in commercial sex. Drug Alcohol Depend. 2008;97(1\u20132):54\u201363.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"2779_CR39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1155\/2015\/904832","volume":"29","author":"SD Shafran","year":"2015","unstructured":"Shafran SD. Hepatitis C and the sex trade. Can J Gastroenterol Hepatol. 2015;29(8):405\u20136.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"2779_CR40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12352","volume":"22","author":"E Gane","year":"2015","unstructured":"Gane E, Kershenobich D, Seguin-Devaux C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. J Viral Hepat. 2015;22(Suppl 1):46\u201373.","journal-title":"J Viral Hepat"},{"issue":"4","key":"2779_CR41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11894-014-0381-5","volume":"16","author":"SK Asrani","year":"2014","unstructured":"Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep. 2014;16(4):381.","journal-title":"Curr Gastroenterol Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2779-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:20:37Z","timestamp":1719555637000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2779-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":41,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2779"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2779-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"article-number":"697"}}